Skip to main content
Top
Published in: Hepatology International 4/2009

01-12-2009 | Original Article

Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas

Authors: Wei-Wen Su, Chien-Hung Chen, Hans Hsienhong Lin, Sheng-Shun Yang, Ting-Tsung Chang, Ken-Sheng Cheng, Jaw-Ching Wu, Shun-Sheng Wu, Chuan-Mo Lee, Chi-Sin Changchien, Chien-Jen Chen, Jin-Chuan Sheu, Ding-Shinn Chen, Sheng-Nan Lu

Published in: Hepatology International | Issue 4/2009

Login to get access

Abstract

Purpose

The proportion of B-HCC cases in Taiwan has progressively decreased over the last 20 years. It was not really due to an overall decrease in B-HCC but due to an increase in HCV-related HCC. The identification of potential HCV endemic areas in Taiwan has consequently become important.

Methods

Data were collected retrospectively from eight Taiwan medical centers from 1981 to 2001, the geographical variations of male C-HCC townships in Taiwan were illustrated on maps. Goodness of fit was used to compare the anti-HCV prevalence in townships and cities, with the mean anti-HCV prevalence for Taiwan as a whole. Township-, city-, and county-specific prevalence of anti-HCV was presented as the median, ranges, and SMRs.

Results

Geographic variation can be analyzed in only 263 townships and cities. The maps were designed on the basis of different SMRs. The mean anti-HCV prevalence for male HCC patients in Taiwan was 31.9% (95% confidence interval: 30.7–33.0). Twenty-five townships distributed throughout central-western and south-western Taiwan have significantly higher prevalence (P < 0.05) (12 townships SMR ≥ 2; 13 townships 1.5 ≤ SMR < 2). Twenty-two townships have significantly lower prevalence (P < 0.05) (6 townships 0.5 ≤ SMR<1; 16 townships SMR < 0.5). Four different patterns of geographic variation in different counties were also noted and demonstrated.

Conclusion

We successfully highlighted some potential high HCV endemic townships in Taiwan.
Literature
1.
go back to reference Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007;96:1127–1134CrossRefPubMed Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007;96:1127–1134CrossRefPubMed
2.
go back to reference Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796–800PubMed Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796–800PubMed
3.
go back to reference Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children, Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855–1859CrossRefPubMed Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children, Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855–1859CrossRefPubMed
4.
5.
go back to reference Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006;11:985–994PubMed Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006;11:985–994PubMed
6.
go back to reference Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119:1946–1952CrossRefPubMed Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119:1946–1952CrossRefPubMed
7.
go back to reference Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol 2007;22:92–98CrossRefPubMed Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol 2007;22:92–98CrossRefPubMed
8.
go back to reference El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750CrossRefPubMed El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750CrossRefPubMed
9.
go back to reference El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27–S34CrossRefPubMed El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27–S34CrossRefPubMed
10.
go back to reference Taura N, Hamasaki K, Nakao K, et al. Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan. Oncol Rep 2006;16:837–843PubMed Taura N, Hamasaki K, Nakao K, et al. Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan. Oncol Rep 2006;16:837–843PubMed
11.
go back to reference Lu SN, Lee CM, Changchien CS, et al. Excess mortality from hepatocellular carcinoma in an HCV-endemic township of an HBV-endemic country (Taiwan). Trans R Soc Trop Med Hyg 1999;93:600–602CrossRefPubMed Lu SN, Lee CM, Changchien CS, et al. Excess mortality from hepatocellular carcinoma in an HCV-endemic township of an HBV-endemic country (Taiwan). Trans R Soc Trop Med Hyg 1999;93:600–602CrossRefPubMed
12.
go back to reference Lu SN, Chue PY, Chen HC, et al. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997;12:547–550CrossRefPubMed Lu SN, Chue PY, Chen HC, et al. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997;12:547–550CrossRefPubMed
13.
go back to reference Wang CS, Chang TT, Chou P. Differences in risk factors for being either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan. J Clin Epidemiol 1998;51:733–738CrossRefPubMed Wang CS, Chang TT, Chou P. Differences in risk factors for being either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan. J Clin Epidemiol 1998;51:733–738CrossRefPubMed
14.
go back to reference Sun CA, Chen HC, Lu SN, et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol 2001;65:30–34CrossRefPubMed Sun CA, Chen HC, Lu SN, et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol 2001;65:30–34CrossRefPubMed
15.
go back to reference Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106:148–155CrossRefPubMed Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106:148–155CrossRefPubMed
16.
go back to reference Chen PF, Kee KM, Chen YD, et al. Village distribution and geographic variations of the prevalence of chronic hepatitis B, C and hypertransaminemia: an analysis of adult health examinations in 520 villages of Tainan County, Taiwan. J Intern Med Taiwan 2006;17:276–290 Chen PF, Kee KM, Chen YD, et al. Village distribution and geographic variations of the prevalence of chronic hepatitis B, C and hypertransaminemia: an analysis of adult health examinations in 520 villages of Tainan County, Taiwan. J Intern Med Taiwan 2006;17:276–290
17.
go back to reference Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2005;165:2206–2212CrossRefPubMed Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2005;165:2206–2212CrossRefPubMed
18.
go back to reference Chou R, Clark EC, Helfand M, et al. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:465–479PubMed Chou R, Clark EC, Helfand M, et al. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:465–479PubMed
19.
go back to reference Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:iii–iv, 1–125 Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:iii–iv, 1–125
Metadata
Title
Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas
Authors
Wei-Wen Su
Chien-Hung Chen
Hans Hsienhong Lin
Sheng-Shun Yang
Ting-Tsung Chang
Ken-Sheng Cheng
Jaw-Ching Wu
Shun-Sheng Wu
Chuan-Mo Lee
Chi-Sin Changchien
Chien-Jen Chen
Jin-Chuan Sheu
Ding-Shinn Chen
Sheng-Nan Lu
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 4/2009
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-009-9146-x

Other articles of this Issue 4/2009

Hepatology International 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.